Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190069 | 0.89 | AVPR1A (0.49) | AVPR1AAVPR2 | |
| SCHEMBL6068933 | 0.86 | AVPR1A (0.59) | AVPR1AAVPR2 | |
| SCHEMBL6068999 | 0.85 | AVPR1A (0.72) | AVPR1AAVPR2 | |
| SCHEMBL6068988 | 0.85 | AVPR1A (0.57) | AVPR1AAVPR2 | |
| SCHEMBL6068950 | 0.85 | AVPR1A (0.57) | AVPR1AAVPR2 | |
| SCHEMBL6069107 | 0.85 | AVPR1A (0.57) | AVPR1AAVPR2 | |
| SCHEMBL3535343 | 0.84 | AVPR1A (0.78) | AVPR1AAVPR2 | |
| SCHEMBL5118045 | 0.83 | AVPR1A (0.62) | AVPR1AAVPR2 | |
| SCHEMBL6068565 | 0.83 | AVPR1A (0.55) | AVPR1AAVPR2 | |
| SCHEMBL5105940 | 0.83 | AVPR2 (0.47) | AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022699-B2 | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH (US) | 2006-04-04 | — | — | US | claimed |
| EP-1377584-B1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH CORP (US) | 2005-02-16 | — | — | EP | claimed |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH | 2002-12-26 | — | — | US | claimed |
| US-7326700-B2 | Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2008-02-05 | — | — | US | disclosed |
| US-7022699-B2 | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-6977254-B2 | Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1377585-B1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1381607-B1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPINE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6903087-B2 | For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1377584-B1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH CORP (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1385849-A1 | NOVEL HYDROXY CYCLOHEXENYL PHENYL CARBOXAMIDES TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1377584-A1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-01-02 | — | — | US | disclosed |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH | 2002-12-26 | — | — | US | disclosed |
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002083684-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPI NE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083679-A1 | NOVEL HYDROXY CYCLOHEXENYL PHENYL CARBOXAMIDES TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083682-A1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083681-A1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, HTR1E, HTR3E | AVPR1A 21/4885AVPR2 46/4885 |
| US-20030055046-A1 | Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, PRLHR | AVPR1A 59/4885AVPR2 74/4885 |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | OXTR, AVPR2, AVPR1B | AVPR1A 4/4885AVPR2 2/4885 |
| US-20030004159-A1 | Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR1A 23/4885AVPR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.